Translate: Programm
English

Vorläufiges Programm

gehe zu Dienstag, 24. Mai

Download detailliertes Programm [PDF]

Montag, 23. Mai

9:00 am

Registration

 

 

 

 

 

 

10:00 am

Welcome

 

 

Georg Schütte

Federal Ministry of Education and Research | State Secretary

 

 

Günther Wess

Helmholtz Association | Vice-President Research Field Health

 

 

Axel Pries

Charité – Universitätsmedizin Berlin | Dean

BIH | Chairman of the Executive Board

 

 

Megan Frisk

Science Translational Medicine | Senior Editor

 

 

Georg Duda

Berlin-Brandenburg Center for Regenerative Therapies | Deputy Director

 

 

 

 

 

10:30 am

Session: Balancing Risks and Benefits in Translational Research
Moderator: Hans-Dieter Volk | Berlin-Brandenburg Center for Regenerative Therapies

 

 

Translational research is hindered by several common obstacles. In addition to insufficient resources and an increasing regulatory burden, there exists a lack of specific mechanisms for considering both the value of the research as well as the risks involved in order to find a proper risk-benefit balance. The session will focus on de-risking strategies that could be implemented to revive and improve processes for translational medicine and contribute more efficiently to clinical success for novel therapeutics and innovative medical devices.

 

 

§  Translational Research within Universities
and beyond

Hans-Gustaf Ljunggren | Karolinska Institutet

 

 

§  Challenges of Moving Academic Research
into the Clinic and beyond

Jeffrey Bluestone | UCSF School of Medicine

 

 

§  Regulatory Aspects in the Translation
of Gene and Cell Therapies

Martina Schuessler-Lenz | Paul-Ehrlich-Institut

 

 

§  Consensus Data Standards – Unified Data for Biomarkers with Focus on Regulatory Science

Klaus Romero | Critical Path Institute

 

 

 

 

 

12:30 pm

Lunch Break

 

 

 

 

 

1:45 pm

Panel: From reactive to proactive translational medicine
Moderator: Georg Duda | Berlin-Brandenburg Center for Regenerative Therapies

 

 

Translational research has been criticized for having little influence on clinical practice. One approach to achieving more relevance is to conduct research using appropriate methods that balance the interests of scientific researchers, clinicians and policymakers. Convening a group of world-renowned experts with varying viewpoints, this panel will focus on different aspects of translation, such as how to assess a candidate project for funding opportunities, how to bring diverse groups to the translational research process, what measures need to be taken to establish a strong clinical research infrastructure, and what is the role of governments in speeding up the translational research process?

 

 

§  Accelerating the Pace at which Lifesaving Treatments Reach Patients

Heyo K. Kroemer | Universitätsmedizin Göttingen

 

 

§  Strengthening External Research Partnerships, Particularly with Industry

Abhay Pandit | National University of Ireland

 

 

§  Governmental Influences on Drug Development: How to Strike a Better Balance?

Günther Wess | Helmholtz Association

 

 

§  How Can Clinicians and Scientists Improve Translation?

Barbara Casadei | University of Oxford

 

 

 

 

 

3:30 pm

Coffee Break

 


4:00 pm

Session: Parallel Breakout Sessions
15 min Introduction by Session Chair

 

In these breakout sessions, participants are broken up into smaller groups for the purpose of discussing specific topics. This session is particularly important in developing, in detail, action items for high-priority areas of translational medicine. The focus lies on synthesizing new ideas and presenting a consensus on Day 2 from the group on how to move forward in various areas.

 

1. Mentoring the Next Generation of Clinical
and Translational Researchers

Chair:     Marc McKee | McGill University
Co-Chair: Georg Duda | Berlin-Brandenburg Center for Regenerative Therapies

 

2. Animal Models in Biomedical Research: Improving Utility and Translation – Cancer Research and Therapeutics as an Example

Chair:     Robert Kerbel | University of Toronto
Co-Chair: Ulrich Dirnagl | Charité Universitätsmedizin - Berlin

 

3. Citizen Science - Opportunities and Challenges for Translational Research

Chair:     Ernst Hafen | ETH Zürich
Co-Chair: Holger Gerhardt | Max Delbrück Center for Molecular Medicine

 

4. Business and Entrepreneurial Aspects of Translational Medicine

Chair:     Glenn Prestwich | University of Utah
Co-Chair: Andrew Williamson | Heraeus Medical GmbH

 

5. Clinical Research Units – Solution for Integrating Translational Research into the Clinical Practice (Industry and Clinical Perspectives )

Chair:     Ronenn Roubenoff | Novartis Institutes for Biomedical Research
Chair:     Barbara Casadei | University of Oxford

Co-Chair: Mohamed Abou El-Enein | Berlin-Brandenburg Center for
   Regenerative Therapies

 

 

 

5:30 pm

Break

 

 

 

6:30 pm

Dinner with Short Talks

 

 

 

 

                Marc McKee | McGill University

                Jackson Orem | Uganda Cancer Institute

 

 

 

 

8:30 pm

End of First Day

Nach oben

Dienstag, 24. Mai

8:45 am

Wake Up & Summary of First Day
David Grainger | University of Utah

 

 

 

9:00 am

Session: Being Efficient in advancing translational research
Moderator: David Grainger | University of Utah

 

Pressing issues in translation are the continuously rising cost of new drugs, especially for serious and life-threatening conditions, and the slow pace of device approval. Drug prices are a result of the complex and lengthy drug development and an approval process that can take a dozen years and billions of dollars. Currently, drug and device development is a rather inefficient and expensive undertaking, which leads to enormous economic burden, lack of innovation and new product introductions. The session will focus on addressing the issue of being efficient in different research fields in order to advance translational research.

 

§  Accelerating Translational Research in Cancer

Robert C. Bast, Jr. | MD Anderson Cancer Center

 

§  New Approaches to Value-Driven Drug Development

Stefanie Dimmeler | University of Frankfurt

 

§  From Systems Biology to Systems Medicine:

The Art is in the Integration

Rudi Balling | University of Luxembourg

 

§  Efficient Translational Strategies:
Innovations that Connect with the Heart

Volkmar Falk | Deutsches Herzzentrum Berlin

 

 

 

11:00 am

Coffee Break

 

 

 

11:30 am

Panel: Summaries of Breakout Sessions

moderator: david grainger | university of utah

 

1. Mentoring the Next Generation of Clinical
 and Translational Researchers

Marc McKee | McGill University  

 

2. Animal Models in Biomedical Research: Improving Utility and Translation – Cancer Research and Therapeutics as an Example

Robert Kerbel | University of Toronto

 

3. Citizen Science - Opportunities and Challenges for Translational Research

Ernst Hafen | ETH Zürich

 

4. Business and Entrepreneurial Aspects of
Translational Medicine

Glenn Prestwich | University of Utah

 

5. Clinical Research Units – Solution for Integrating Translational Research into the Clinical Practice. Industrial and Clinical Perspectives

Ronenn Roubenoff | Novartis Institutes for Biomedical Research

 

 

 

1:00 pm

Lunch Break

 


 

2:15 pm

Session: Translational Medicine Successes in Global Health
Moderator: Megan Frisk | Science Translational Medicine

 

The progress of translational medicine has attracted attention of the scientific community and it has been linked to promising potential for global health gain. However, there are still major obstacles related to patent protection, funding and delivering new treatments faster to patients in need. This session will focus on addressing the issues of how important translational medicine is becoming to medical practice, and how far it still has to go to benefit the global community.

 

§  Regenerative Medicine Build-Out for an Aging Global Population

Andre Terzic | Mayo Clinic

 

§  Developing Critical Research and Training Infrastructure with Limited Resources

Jackson Orem | Uganda Cancer Institute

 

§  The Art of Funding Biomedical Innovation:
A Global Perspective

Edward Holmes | University of California

 

§  Accelerating the Translation of Global Health Innovations Toward Real Solutions for the Benefit of Patients

Steve Kern | Bill & Melinda Gates Foundation

 

§  Evaluating and Developing Translational Products

David Mooney | Harvard University

 

 

 

4:30 pm

Closing Remarks
Megan Frisk | Science Translational Medicine
Georg Duda | Berlin-Brandenburg Center for Regenerative Therapies

 

 

Nach oben